Medical News's Articles in Lung-Mesothelioma-Asbestos

Approval Within 24 Hours
We are shifting DB. Members may see some problems

Search:

Show All\|Display Category\|Title\|Newest\|Oldest
Novel Treatment Approach For Lung Cancer At The University Of Pittsburgh Medical Center (UPMC) Clinicians at the University of Pittsburgh Medical Center (UPMC) Cancer Centers successfully treated a lung cancer patient in her mid-fifties using a new more precise technique that combines image-guided radiotherapy (IGRT) with respiratory gating to zero in on her tumor while adapting for breathing motion. The new tissue sparing procedure was made possible using advanced imaging and treatment technology from Varian Medical Systems (NYSE: VAR) of Palo Alto, California. First-ever Genomic Test Predicts Which Lung Cancer Patients Need Chemotherapy To Live Duke University Medical Center scientists have developed the first-ever genomic test to predict which patients with early-stage lung cancer will need chemotherapy to live and which patients can avoid the toxic regimen of drugs. Spectrum Pharmaceuticals Announces Initiation Of Phase 2 Trial Evaluating Satraplatin Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) announced today that its partner, GPC Biotech, has initiated a Phase 2 randomized trial evaluating satraplatin in combination with Tarceva(R) (erlotinib) as a first-line therapy in patients with inoperable, advanced non-small cell lung cancer (NSCLC) who are 70 years of age and older. GPC Biotech Initiates Phase 2 Randomized Trial Evaluating Satraplatin Plus Tarceva(R) In Patients GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq: GPCB) today announced the initiation of a Phase 2 randomized trial evaluating the Company's lead drug candidate, satraplatin, in combination with Tarceva(R) (erlotinib) as a first-line therapy in patients with inoperable advanced non-small cell lung cancer (NSCLC) who are 70 years of age and older. Spectrum Pharmaceuticals Announces Initiation Of Phase 2 Trial For Patients With Inoperable Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) announced today that its partner, GPC Biotech, has initiated a Phase 2 randomized trial evaluating satraplatin in combination with Tarceva(R) (erlotinib) as a first-line therapy in patients with inoperable, advanced non-small cell lung cancer (NSCLC) who are 70 years of age and older. Researchers Develop Blood Test To Detect Lung Cancer Lung cancer is the leading cause of cancer death for both men and women in the United States and around the world, mainly because lung cancers are found in late stages and the best treatment opportunities already have been missed. In Kentucky, the incidence of lung cancer is 49 percent higher than the national rate. However, a new blood test being developed at the University of Kentucky could soon change all that.

Free Content
Free content from users at Onlypunjab.com
Our Traffic Rankings

Submit Articles
Member Login
Top Authors
Most Popular Articles
Submission Guidelines
Ezine Notifications
Article RSS Feeds

New Stuff
About Us
Site Blog
Forum
Link to Us
Contact Us
Privacy Policy
Terms of Service

Arts and Entertainment
Astrology
Casino-Gambling
Humanities
Humor
Language
Movies
Music
Philosophy
Photography
Poetry
Tattoos
Automotive
Mobile-Audio-Video
Motorcycles
Trucks
Business
Advertising
Branding
Careers-Employment
Change-Management
Customer-Service
Entrepreneurialism
Ethics
Management
Marketing
Marketing-Direct
Negotiation
Networking
Outsourcing
PR
Presentation
Resumes-Cover-Letters
Sales
Sales-Management
Sales-Teleselling
Sales-Training
Small-Business
Strategic-Planning
Team-Building
Top7-or-10-Tips
Workplace and Communication
Cancer
Breast-Cancer
Colon-Rectal-Cancer
Leukemia-Lymphoma-Cancer
Lung-Mesothelioma-Asbestos
Ovarian-Cervical-Uterine-Cancer
Prostate-Cancer
Skin-Cancer
Communications
Computer
Certification-Tests
Data Recovery
Games
Hardware
Mobile-Computing
Personal Technology
Software
PHP
Web
html
Family
Babies-Toddler
Crafts-Hobbies
Elder Care
Holidays
Home Appliances
Home Audio/Video
Home Improvement
Home Security
Interior Decorating
Kids
Landscaping-Gardening
Parental Care
Pets
Pregnancy
Bankruptcy
Credit
Currency Trading
Debt Consolidation
Debt-Relief
Estate Plan Trusts
Insurance
Investments
Loans
Mortgages
Mutual Funds
Personal Finance
Real Estate
Real Estate FSBO
Structured Settlements
Taxes
Wealth Building
Food and Drink
Chocolate
Coffee
Cooking-Tips
Recipes
Wine-Spirits
Health
Acne
Aerobics Cardio
Alternative
Anti Aging
Beauty
Build Muscle
Depression
Diabetes
Exercise
Fitness Equipments
Hair Loss
Medicine
Meditation
Mens Issues
No Smoking
Nutrition
Obesity
Polution
Sidha
Supplements
Weight Loss
Womens Issues
Yoga
Home Based Business
Network-Marketing
Internet and Businesses Online
Affiliate-Revenue
Auctions
Audio-Streaming
Autoresponders
Blogging
Domain-Names
E-Books
Ecommerce
Email-Marketing
Ezine-Publishing
Forums
Internet-Marketing
List-Building
Podcasting
RSS
Security
Spam-Blocker
Video-Streaming
Web-Design
Web-Development
Web-Hosting
Kids and Teens
Legal
Identity-Theft
Living-Will
News and Society
Dating
Divorce
Economics
Love
Marriage-Wedding
Politics
Relationships
Religion
Sexuality
Reference and Education
College University
Education
Future Concepts
Home-Schooling
Science
Self Improvement
Addictions
Anger-Management
Attraction
Coaching
Creativity
Goal-Setting
Grief-Loss
Happiness
Innovation
Inspirational
Leadership
Motivation
Organizing
Positive-Attitude
Spirituality
Stress-Management
Success
Time-Management
Shopping and Product Reviews
Book-Reviews
Fashion-Style
Jewelry-Diamonds
Sport
Baseball
Cycling
Fishing
Football
Golf
Martial Arts
Running
Soccer
Swimming
Triathlon
Technology
Broad band
GPS
Mobile
Statellite
Video Conferencing
VOIP
Travel and Leisure
Aviation
Cruising-Sailing
Outdoors
Vacation-Rentals
Website Promotion
PPC-Advertising
SEO
Site-Promotion
Traffic-Building
Womens Interests
Writing and Speaking
Book-Marketing
Copywriting
Public-Speaking
Teleseminars
Writing
Writing-Articles

| |